FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3022617785> ?p ?o ?g. }

• W3022617785 endingPage "e0232768" @default.
• W3022617785 startingPage "e0232768" @default.
• W3022617785 abstract "Background Intensive care unit (ICU) patients with the most severe forms of acute coronary syndrome (ACS) require invasive therapies such as extracorporeal life support. The risk of bleeding in ICU patients with ACS treated with a dual antiplatelet therapy of aspirin and ticagrelor is unknown. The primary objective of this study was to compare the bleeding risk of ticagrelor and clopidogrel in ICU patients with ACS. Methods and findings We conducted a retrospective study based on a propensity score and a proportional hazards model. All patients with ACS hospitalized in the ICU of a French university hospital between January 2013 and January 2017 were included in the study. Bleeding during ICU stay was defined as all Thrombolysis in myocardial infarction (TIMI) major or minor events. A total of 155 patients were included in the study. According to propensity score matching, 57 patients treated with aspirin and ticagrelor were matched with 57 patients treated with aspirin and clopidogrel. Median (first-third quartile) Simplified Acute Physiology Score II was 61.5 (41.0–85.0). Bleeding during ICU stay occurred in 12 patients (21.1%) treated with clopidogrel and in 35 patients (61.4%) treated with ticagrelor (p<0.0001). This significant association was found for both TIMI major bleeding (12.3% vs. 35.1%, p = 0.004) and TIMI minor bleeding (8.8% vs. 26.3%, p = 0.01). The relative risk of bleeding occurrence during ICU stay was 2.60 (confidence interval 95%: 1.55–4.35) for ticagrelor compared to clopidogrel. No significant difference in ICU mortality was found between the two groups (45.6% in the clopidogrel group vs. 29.8% in the ticagrelor group, p = 0.08). Conclusions Bleeding complications are frequent and serious in ICU patients with ACS. A dual antiplatelet therapy of aspirin and ticagrelor is associated with a higher risk of bleeding compared to a dual antiplatelet therapy of aspirin and clopidogrel." @default.
• W3022617785 created "2020-05-13" @default.
• W3022617785 creator A5004148832 @default.
• W3022617785 creator A5013816217 @default.
• W3022617785 creator A5022988814 @default.
• W3022617785 creator A5032094540 @default.
• W3022617785 creator A5037933560 @default.
• W3022617785 creator A5045347797 @default.
• W3022617785 creator A5046138010 @default.
• W3022617785 creator A5060838105 @default.
• W3022617785 creator A5073750494 @default.
• W3022617785 creator A5085404520 @default.
• W3022617785 date "2020-05-04" @default.
• W3022617785 modified "2023-10-11" @default.
• W3022617785 title "Bleeding risk of ticagrelor compared to clopidogrel in intensive care unit patients with acute coronary syndrome: A propensity-score matching analysis" @default.
• W3022617785 cites W1582447064 @default.
• W3022617785 cites W175512219 @default.
• W3022617785 cites W1983126671 @default.
• W3022617785 cites W1995122441 @default.
• W3022617785 cites W2009741254 @default.
• W3022617785 cites W2085826947 @default.
• W3022617785 cites W2100518568 @default.
• W3022617785 cites W2104595603 @default.
• W3022617785 cites W2127244250 @default.
• W3022617785 cites W2130369043 @default.
• W3022617785 cites W2131181128 @default.
• W3022617785 cites W2140501627 @default.
• W3022617785 cites W2144845635 @default.
• W3022617785 cites W2153631612 @default.
• W3022617785 cites W2155645310 @default.
• W3022617785 cites W2166950143 @default.
• W3022617785 cites W2168458505 @default.
• W3022617785 cites W2169387542 @default.
• W3022617785 cites W2407690838 @default.
• W3022617785 cites W2419503184 @default.
• W3022617785 cites W2509712226 @default.
• W3022617785 cites W2522187540 @default.
• W3022617785 cites W2597486205 @default.
• W3022617785 cites W2599076725 @default.
• W3022617785 cites W2741901982 @default.
• W3022617785 cites W2752033985 @default.
• W3022617785 cites W2888543854 @default.
• W3022617785 cites W2891670573 @default.
• W3022617785 cites W2905071154 @default.
• W3022617785 cites W2916912835 @default.
• W3022617785 cites W2938138790 @default.
• W3022617785 cites W2938879373 @default.
• W3022617785 cites W4235711314 @default.
• W3022617785 cites W4247529334 @default.
• W3022617785 cites W4248429808 @default.
• W3022617785 cites W4361794418 @default.
• W3022617785 doi "https://doi.org/10.1371/journal.pone.0232768" @default.
• W3022617785 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7197796" @default.
• W3022617785 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32365100" @default.
• W3022617785 hasPublicationYear "2020" @default.
• W3022617785 type Work @default.
• W3022617785 sameAs 3022617785 @default.
• W3022617785 citedByCount "9" @default.
• W3022617785 countsByYear W30226177852021 @default.
• W3022617785 countsByYear W30226177852022 @default.
• W3022617785 crossrefType "journal-article" @default.
• W3022617785 hasAuthorship W3022617785A5004148832 @default.
• W3022617785 hasAuthorship W3022617785A5013816217 @default.
• W3022617785 hasAuthorship W3022617785A5022988814 @default.
• W3022617785 hasAuthorship W3022617785A5032094540 @default.
• W3022617785 hasAuthorship W3022617785A5037933560 @default.
• W3022617785 hasAuthorship W3022617785A5045347797 @default.
• W3022617785 hasAuthorship W3022617785A5046138010 @default.
• W3022617785 hasAuthorship W3022617785A5060838105 @default.
• W3022617785 hasAuthorship W3022617785A5073750494 @default.
• W3022617785 hasAuthorship W3022617785A5085404520 @default.
• W3022617785 hasBestOaLocation W30226177851 @default.
• W3022617785 hasConcept C126322002 @default.
• W3022617785 hasConcept C164705383 @default.
• W3022617785 hasConcept C167135981 @default.
• W3022617785 hasConcept C17923572 @default.
• W3022617785 hasConcept C2776376669 @default.
• W3022617785 hasConcept C2777028646 @default.
• W3022617785 hasConcept C2777628954 @default.
• W3022617785 hasConcept C2777698277 @default.
• W3022617785 hasConcept C2777849778 @default.
• W3022617785 hasConcept C2777995511 @default.
• W3022617785 hasConcept C2780400711 @default.
• W3022617785 hasConcept C2780890252 @default.
• W3022617785 hasConcept C500558357 @default.
• W3022617785 hasConcept C71924100 @default.
• W3022617785 hasConceptScore W3022617785C126322002 @default.
• W3022617785 hasConceptScore W3022617785C164705383 @default.
• W3022617785 hasConceptScore W3022617785C167135981 @default.
• W3022617785 hasConceptScore W3022617785C17923572 @default.
• W3022617785 hasConceptScore W3022617785C2776376669 @default.
• W3022617785 hasConceptScore W3022617785C2777028646 @default.
• W3022617785 hasConceptScore W3022617785C2777628954 @default.
• W3022617785 hasConceptScore W3022617785C2777698277 @default.
• W3022617785 hasConceptScore W3022617785C2777849778 @default.
• W3022617785 hasConceptScore W3022617785C2777995511 @default.
• W3022617785 hasConceptScore W3022617785C2780400711 @default.
• W3022617785 hasConceptScore W3022617785C2780890252 @default.

• next